Evotec & Takeda: strategic RNA alliance

Evotec SE today announced that the Company has entered into a multi-RNA target alliance with Takeda Pharmaceutical Company Limited (“Takeda”) with the goal to discover and develop RNA targeting small molecule therapeutics for highly attractive targets that are difficult to address via more conventional approaches.

Evotec and Takeda will jointly identify and develop small molecules targeting a range of RNA targets aligned with Takeda’s research and development areas. The collaboration will leverage Evotec’s extensive RNA targeting platform to optimally identify promising RNA sequences to target with small molecule ligands that can be developed into potentially first-in-class therapeutics.

Under the terms of the agreement, Evotec will receive significant research funding and will be eligible to receive discovery, pre-clinical, clinical, commercial and sales milestone payments of up to US$ 160 m per programme. Additionally, Evotec is entitled to tiered royalties on net sales of any products resulting from the collaboration.

Dr Cord Dohrmann, Chief Scientific Officer of Evotec, commented: “Many highly validated targets have proven to be intractable via conventional protein targeting approaches. For this reason, Evotec has been pioneering RNA targeting strategies and approaches for quite some time. We are very excited about the opportunity to collaborate with Takeda in this field as both companies share the vision to jointly develop small molecule therapeutics against high value RNA targets that will deliver long awaited therapeutics.”

“Takeda recognizes targeting RNA with small molecules as a promising new modality that has tremendous potential for much needed medicines for patients through modulating historically undruggable targets”, said Dr Larry Hamann, Head, Drug Discovery Sciences, Takeda. “We are excited to be working with Evotec and their impressive capabilities.”

More News

At its new premises in the tecHHub Hamburg, CrystalsFirst is significantly expanding its operations to foster greater synergy. (Picture: CrystalsFirst)
At its new premises in the tecHHub Hamburg, CrystalsFirst is significantly expanding its operations to foster greater synergy. (Picture: CrystalsFirst)

CrystalsFirst Scales Operations...

CrystalsFirst, a leading provider of advanced structural biology solutions and AI-driven drug discovery, is pleased to announce a multi-million-euro expansion of its laboratory infrastructure and ...

Read more …
Evotec has started the search for a permanent solution for the position of CEO.

Evotec announces CEO transition

Evotec SE announced that after close to 15 years of successful service, CEO Dr Werner Lanthaler has informed the company, that he will not continue ...

Read more …
Johanna Hakanpää, scientist in charge of beamline P11, in conversation with Serghei Glinca, founder and CEO of CrystalsFirst. ( Photo: DESY)
Johanna Hakanpää, scientist in charge of beamline P11, in conversation with Serghei Glinca, founder and CEO of CrystalsFirst. ( Photo: DESY)

Cooperation for faster drug discovery

The mutual project “LigandML” receives funding by the IFB Hamburg aiming to leverage experimental capabilities for better data quality paired ...

Read more …